New Clinical Data in Japan Demonstrates Benefits of Using Vycor Medical's VBAS with Karl Storz's VITOM Exoscope for Surgery of Deep-Seated Tumors

BOCA RATON, Florida, October 28, 2015 /PRNewswire/ --

Vycor Medical, Inc. (OTCQB: VYCO) reports that a new peer-reviewed study of its FDA-approved ViewSite™ Brain Access System (VBAS) was published in the latest issue of Japanese Journal of Neurosurgery.

The study, titled "Exoscope-Assisted Surgery for Deep-Seated Intraparenchymal Tumor," emphasizes the usefulness of VBAS, a clear tube retractor, in combination with Karl Storz's VITOM® telescope, an exoscope visualization device, for biopsy or removal of deep-seated tumors, including thalamic gliomas and malignant lymphomas.

The study found that the combined use of these devices is very promising for surgery involving deep-seated tumors given how the VITCOM telescope provides a further working distance and clear view from outside the operation field.

"This peer-reviewed study highlights the growing acceptance of VBAS in the international markets and its potential use with other minimally invasive devices," said Peter Zachariou, CEO of Vycor. "This high-quality clinical data can help support the greater usage of VBAS and its adoption as the standard of care for brain retraction and access."

The article is the sixth VBAS study to be published this year, including one featured on the cover of the Journal of Neurosurgery. It is also the second clinical paper for VBAS published in Japan, following the article titled, "Rigid Endoscopic Resection of Deep-Seated or Intra-ventricular Brain Tumors." This article, authored by researchers at Sapporo Medical University's Department of Neurosurgery, highlights a novel rigid endoscopic resection technique utilizing VBAS as a safer, more reliable and less invasive method for the treatment of deep-seated brain tumors.

Vycor also recently announced two new ViewSite TC model devices that are half the diameter of the previously smallest VBAS device. The smaller product line was developed in close collaboration with a leading neurosurgeon who identified a need for a much smaller VBAS that would allow for less invasive surgery, yet still enable the use of instruments such as endoscopes. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles.

About ViewSite™ Surgical Access System 

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community.

The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS, see VBAS Video.

About Vycor Medical 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

For the latest information on the company, including media and other coverage, and to learn more, visit http://www.vycormedical.com, http://www.vycorvbas.com or http://www.novavision.com.    

Investor Relations:
Liolios
Ronald A. Both, Senior Managing Director
Tel 1-949-574-3860
[email protected]

SOURCE Vycor Medical, Inc.